Atrial Fibrillation

Detection and real-time treatment of Atrial Fibrillation (AF) is a major unmet need worldwide.

Scope of the Problem

Over 52 million individuals worldwide have AF, leading to expenditures of over $500 billion per year.

Clinical Problems

Monitoring - Once AF is detected, identification of its continued presence and recurrence requires a monitoring device in most patients.

Intolerable Symptoms - Over 20% of AF patients have intolerable symptoms and seek ablation, rhythm control or AF prevention with medications.

Management of AF

Risks of Ablation - Ablation and medications to prevent AF are not always effective and carry significant risks.

Anti-coagulation - To reduce the risk of stroke, most patients with AF require expensive, lifelong anticoagulation, which increases bleeding risk.

Anti-coagulation post AF ablation - In patients with a high risk of stroke, termination of AF by current methods, which do not act rapidly, does not remove the need for lifelong anticoagulation.

LAA closure does not prevent AF - implantation in the left atrial appendage reduces stroke risk in AF patients at high risk of bleeding, but does not decrease the risk of symptomatic AF.